Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia

@inproceedings{Blunt2015PharmacologicalTO,
  title={Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia},
  author={Matthew D. Blunt and Andrew J Steele},
  booktitle={Leukemia research reports},
  year={2015}
}
PI3Kδ inhibitors such as idelalisib are providing improved therapeutic options for the treatment of chronic lymphocytic leukaemia (CLL). However under certain conditions, inhibition of a single PI3K isoform can be compensated by the other PI3K isoforms, therefore PI3K inhibitors which target multiple PI3K isoforms may provide greater efficacy. The… CONTINUE READING